At the end of the survey you are given a code that will disable the survey pop-up in the future. The program opens with a pop-up window encouraging you to take a survey about your weight loss plans. Although it works well enough, it's not nearly as full-featured as similar programs we've seen. eFit Free Edition is a basic meal planner and weight tracker that lets you keep a record of your food intake.
RBL is an author of several papers cited in this topic.Weight loss is a multibillion-dollar industry in the United States, and it's no surprise that software developers want a piece of that action. He has received royalties from Blackwell Press as an editors of a textbook International Neurology.
RPL has received clinical trial grants (no direct payments) for studies in myasthenia gravis (Alexion, Argenx, Ra Pharmaceuticals) and MS (Novartis, Teva, Genentech/Roche, Chugai). RPL has presented several CME talks for companies with multiple sources of support (no direct payments to RBL). secondary progressive MS) GLG Consulting, Putnam Consulting, Slingshot Consulting, Haven Consulting, Clearview Consulting, Alpha Sites Consulting, and Insights Consulting (providing insights on the current and future treatments of several neuroimmunologic diseases including MS, MG, Guillain-Barré syndrome, CIDP, and neuromyelitis optica spectrum disorder) and Teva Pharmaceuticals (two non-branded talks to patient groups about MS). RPL has worked with Alexion (testing a treatment for myasthenia gravis) Novartis (design of research related to primary progressive MS vs. RPL is an Advisory Board member for Argenx (developing a clinical trial for chronic inflammatory demyelinating polyneuropathy ). Wayne State University School of Medicine Most patients, but not all, enjoy good quality of life and normal lifespan due to advances in diagnosis and in immunosuppressive and immunomodulatory treatment. It is not yet clear at which stages of MG, in which patients, and in what sequence in relation to other therapies, that thymectomy in non-thymoma patients should be done.Įculizumab, a monoclonal antibody that inhibits complement activation, has shown clinical benefit in patients with treatment-resistant generalised MG and AChR antibodies.Īpproximately 15% to 20% of patients with MG experience a myasthenic crisis (exacerbation necessitating mechanical ventilation). Thymectomy has also been shown to be effective in people with generalised MG without thymoma who are AChR antibody positive. Treatments include anticholinesterases and immunotherapy. Patients with MG may have elevated levels of one or more of these antibodies.Ĭlinical electrophysiology shows decremental response on repetitive nerve stimulation or increased jitter on single-fibre study. Antibodies have also been identified to proteins located at the neuromuscular junction: low-density lipoprotein receptor-related protein 4 (LRP4), agrin, collagen Q, and cortactin. It commonly presents with drooping eyelids, double vision, oropharyngeal and/or appendicular weakness, and shortness of breath.Įlevated serum levels of antibodies against the acetylcholine receptor (AChR) or muscle-specific tyrosine kinase (MuSK) are usually present.
MG is characterised by muscle weakness that increases with exercise (fatigue) and improves on rest. Myasthenia gravis (MG) is a chronic autoimmune disorder of the post-synaptic membrane at the neuromuscular junction in skeletal muscle.